March 22nd 2023
Results from the phase 3 DERMIS-1 and DERMIS-2 trials were presented at the 2023 American Academy of Dermatology Annual Meeting.
December 21st 2021
December 21st 2021
December 8th 2021
Phase 3 results show risankizumab outperforms secukinumabJanuary 17th 2020
Risankizumab (SKYRIZI, AbbVie), outperformed secukinumab (Cosentyx, Novartis) in a head-to-head phase 3 study comparing the two treatments in adult patients with moderate to severe plaque psoriasis, according to data released by the company Jan. 14.
Phototherapy safe, effective for psoriasisNovember 8th 2019
The 2019 joint American Academy of Dermatology and National Psoriasis Foundation phototherapy treatment of psoriasis guidelines comprehensively updates dermatologists and other providers on the state-of-the art use of various light modalities to treat psoriasis patients.
Behavioral modifications may reduce psoriasis severitySeptember 6th 2019
Researchers in Taiwan investigated whether behavioral modifications such as weight reduction, alcohol abstinence, smoking cessation and exercise could impact psoriasis severity. Read what they discovered in this article.
Joint AAD, NPF phototherapy guidelinesSeptember 5th 2019
Discover key takeaways from the American Academy of Dermatology and National Psoriasis Foundation joint guidelines for the management and treatment of psoriasis with phototherapy published in the September issue of the Journal of American Academy of Dermatology.
The evolving landscape of pediatric psoriasisJuly 23rd 2019
About one-third of patients with psoriasis are children or adolescents. Still, little research exists on treating this patient population. New disease management guidelines and emerging studies seek to fill the gap.
Patient satisfaction in psoriasisJuly 9th 2019
There are more treatment options for psoriasis patients than ever before, so why do patient reported outcomes still suggest failure to meet patient expectations? Experts from the International Psoriasis Council (IPC) highlight factors that could be causing the perceived disparity between psoriasis treatment and patient satisfaction.
Can psychotherapy help psoriasis patients?July 9th 2019
Do you recommend psychotherapy to your psoriasis patients? While there is a well-established connection between psoriasis and mental health, there is little data available on the impact of psychological interventions on psoriasis. These study authors look to fill that gap.
Brodalumab effective for psoriasis patients with skin of colorMay 23rd 2019
Psoriasis patients with skin of color experience psoriasis differently, often reporting worse health related quality of life outcomes compared to their Caucasian peers. Brodalumab may help, suggests a recent study.
Consider more than severity, spread in psoriasisMay 22nd 2019
The evaluation of psoriasis requires more than simply checking the severity and spread of the disease, a new report suggests. Rather, physicians should try to distinguish between stable and active disease with an eye toward the wider body-wide effects of the latter form.
Cognitive behavioral therapy effective for psoriasisMay 13th 2019
Cognitive behavioral therapy (CBT) can successfully treat the physical symptoms of psoriasis and systemic treatment doesn't seem to provide an extra boost to its effectiveness, a new systematic review and meta-analysis finds.
A patient-centered approach to psoriasis treatmentApril 22nd 2019
In psoriasis, many therapies offer roughly the same level of care, but that doesn’t mean any patient will respond well to any therapy. According to Mark Lebwohl, M.D., physicians should consider each treatment option in light of a patient's specific comorbidities.
Researchers found a significant inverse correlation between ustekinumab levels and PASI scores at week 52, suggesting that drug levels are associated with the change in the treatment response. Measuring ustekinumab levels can have major clinical implications.
Utility of the methotrexate test doseMarch 6th 2019
Guidelines suggest that providing a small test dose of methotrexate to patients followed by laboratory evaluation can minimize the risk of serious adverse events associated with methotrexate. This small retrospective study examined whether methotrexate requires a test dose.